Reproductive Considerations for Transgender Patients — MCQs
A teenage girl presented with irregular cycles and increased facial hair. Her ovaries showed increased volume. Which of the following are used in the first line treatment? 1. Laparoscopic ovarian drilling 2. Anti-androgens 3. Lifestyle modifications 4. Combined oral contraceptive pills
Which of the following is a method of natural family planning that involves tracking basal body temperature?
Which of the following hormones will be affected most after the change in sex hormone binding globulin?
Congenital adrenal hyperplasia most commonly presents as
All are steps of GIFT, except:
Continuous GnRH therapy is used in All EXCEPT.
What is the most distinctive functional characteristic of the barrier method shown?
A multidisciplinary team is developing protocols for adolescent gender-affirming care. When evaluating the appropriateness of GnRH analog therapy versus immediate cross-sex hormones in a 16-year-old with persistent gender dysphoria (Tanner stage 5), which factor most strongly supports proceeding directly to cross-sex hormones?
A 35-year-old transgender woman desires fertility preservation before starting feminizing hormone therapy. She has limited financial resources. Which option provides the best balance of efficacy, cost, and time efficiency?
A 28-year-old transgender man presents 6 months after initiating testosterone therapy with persistent vaginal bleeding despite amenorrhea for 4 months. Labs show testosterone 650 ng/dL and hemoglobin 9.2 g/dL. What is the most appropriate next step?
Reproductive Considerations for Transgender Patients Indian Medical PG Practice Questions and MCQs
Question 1: A teenage girl presented with irregular cycles and increased facial hair. Her ovaries showed increased volume. Which of the following are used in the first line treatment? 1. Laparoscopic ovarian drilling 2. Anti-androgens 3. Lifestyle modifications 4. Combined oral contraceptive pills
- A. 2,3,4 (Correct Answer)
- B. 1,2,3
- C. 1,2,4
- D. 1,3,4
Explanation: ***2,3,4 (Correct Answer)*** - **Lifestyle modifications (3)** are the foundational first-line intervention for all PCOS patients, particularly those who are overweight or obese, as they improve insulin sensitivity, reduce androgen levels, and improve both metabolic and reproductive outcomes. - **Combined oral contraceptive pills/COCs (4)** are the first-line pharmacological treatment for menstrual irregularity and hyperandrogenism in PCOS when fertility is not desired. They regulate cycles, suppress ovarian androgen production, and reduce hirsutism and acne. - **Anti-androgens (2)** such as spironolactone are used in first-line management of moderate-to-severe hirsutism and acne in PCOS, typically in combination with COCs. They block androgen receptors or inhibit androgen synthesis, providing additional benefit for hyperandrogenic symptoms like the increased facial hair in this patient. *1,2,3* - **Laparoscopic ovarian drilling (1)** is a second-line surgical treatment reserved for anovulatory infertility in PCOS patients who fail to respond to ovulation induction with clomiphene citrate. It is NOT a first-line treatment for menstrual irregularity and hirsutism. - While lifestyle modifications (3) and anti-androgens (2) are appropriate first-line components, the inclusion of ovarian drilling makes this combination incorrect as a first-line approach. *1,2,4* - **Laparoscopic ovarian drilling (1)** is an invasive procedure indicated only as second-line therapy for specific cases of anovulatory infertility, not for initial management of irregular cycles and hirsutism. - Although anti-androgens (2) and COCs (4) are appropriate first-line pharmacological treatments, the inclusion of ovarian drilling excludes this from being a correct first-line treatment combination. *1,3,4* - This combination includes two appropriate first-line treatments: **lifestyle modifications (3)** and **combined oral contraceptive pills (4)**. - However, **laparoscopic ovarian drilling (1)** is a second-line or third-line surgical intervention for very specific indications (anovulatory infertility resistant to medical management), making this combination incorrect as a first-line approach for this clinical presentation.
Question 2: Which of the following is a method of natural family planning that involves tracking basal body temperature?
- A. Coitus interruptus (withdrawal method)
- B. Safe period (calendar method)
- C. Basal body temperature (BBT) method (Correct Answer)
- D. Abstinence (not having sexual intercourse)
Explanation: ***Basal body temperature (BBT) method*** - The **basal body temperature** (BBT) method relies on a slight increase in a woman's resting body temperature, typically by 0.5 to 1.0°F, occurring after **ovulation**. - This temperature shift signals that ovulation has occurred, allowing couples to identify the **fertile window** and avoid intercourse during that time. - This method involves tracking daily basal body temperature to predict ovulation. *Coitus interruptus (withdrawal method)* - This method involves the male withdrawing his penis from the vagina just before **ejaculation**. - It does not involve tracking **basal body temperature** and has a higher failure rate compared to many other contraceptive methods due to potential pre-ejaculatory fluid containing sperm. *Safe period (calendar method)* - The calendar method, also known as the **rhythm method** or **Ogino-Knaus method**, estimates the fertile window based on the typical length of a woman's menstrual cycles. - This method relies on calculating the approximate times of ovulation and avoiding intercourse during those days; it does not involve daily **temperature tracking**. *Abstinence (not having sexual intercourse)* - **Abstinence** involves completely refraining from sexual intercourse and is the only 100% effective method of preventing pregnancy and sexually transmitted infections (STIs). - This method does not involve any form of physical tracking, such as **basal body temperature**, as there is no risk of conception.
Question 3: Which of the following hormones will be affected most after the change in sex hormone binding globulin?
- A. Testosterone (Correct Answer)
- B. Progesterone
- C. DHEA
- D. Estrogen
Explanation: ***Testosterone*** - **Sex hormone-binding globulin (SHBG)** binds primarily to **testosterone** (and dihydrotestosterone) with **high affinity**. - SHBG has approximately **5 times greater affinity** for testosterone compared to estradiol. - A change in SHBG levels will significantly impact the proportion of **free (biologically active) testosterone** available in the circulation, thus affecting its overall function and measurement. - This makes testosterone the hormone **most affected** by changes in SHBG levels. *Progesterone* - **Progesterone** is primarily bound to **albumin** and **corticosteroid-binding globulin (CBG)**, not SHBG. - Therefore, changes in SHBG would have minimal direct impact on progesterone levels or its bioavailability. *DHEA* - **Dehydroepiandrosterone (DHEA)** is mostly bound to **albumin** in the blood. - Its binding to SHBG is negligible, making changes in SHBG irrelevant to its overall circulating levels or activity. *Estrogen* - **Estrogen (estradiol)** also binds to SHBG, but with **significantly lower affinity** than testosterone (approximately 5-fold less). - While affected by SHBG changes, the impact is less pronounced than on testosterone due to the lower binding affinity and its additional binding to albumin.
Question 4: Congenital adrenal hyperplasia most commonly presents as
- A. 46,XY DSD
- B. Ovotesticular DSD
- C. 46,XX DSD with virilization (Correct Answer)
- D. 46,XY DSD with undervirilization
Explanation: ***46,XX DSD with virilization*** (formerly female pseudohermaphroditism) - This is the **most common presentation** of congenital adrenal hyperplasia (CAH), particularly due to **21-hydroxylase deficiency**, which accounts for >90% of CAH cases. - Affects genetically female (46,XX) individuals with excess **androgens** produced by hyperplastic adrenal glands leading to **virilization** of external genitalia. - Clinical features include **clitoromegaly, labioscrotal fusion**, and varying degrees of masculinization, while **internal female organs (uterus, ovaries, fallopian tubes) remain normal**. - This is the classic presentation that brings CAH to clinical attention in newborn screening programs. *46,XY DSD* (formerly 46,XY intersex) - This terminology refers to conditions where genetically male individuals (46,XY) have atypical genital development. - Common causes include **androgen insensitivity syndrome** or disorders of testosterone synthesis (5α-reductase deficiency, 17β-hydroxysteroid dehydrogenase deficiency). - CAH in 46,XY individuals typically presents with **isosexual precocious pseudopuberty** (early virilization) in simple virilizing forms or **salt-wasting adrenal crisis** in severe forms, not undervirilization. *Ovotesticular DSD* (formerly true hermaphroditism) - Very rare condition where an individual has **both ovarian and testicular tissue**, either as separate gonads or combined as ovotestes. - Often involves complex chromosomal patterns including **46,XX/46,XY mosaicism** or 46,XX with SRY translocation. - Not related to CAH pathophysiology, which involves enzymatic defects in steroidogenesis. *46,XY DSD with undervirilization* (formerly male pseudohermaphroditism) - Occurs when 46,XY individuals have **undervirilized or ambiguous external genitalia** due to impaired androgen synthesis or action. - Causes include disorders of testicular development, androgen biosynthesis defects, or **androgen insensitivity**. - While CAH can affect males, it causes **excess androgens** leading to precocious puberty, not undervirilization.
Question 5: All are steps of GIFT, except:
- A. Transfer of unfertilized egg into the fallopian tube
- B. Fertilization of oocyte in lab (Correct Answer)
- C. Ovulation stimulation
- D. Oocyte retrieval
Explanation: ***Fertilization of oocyte in lab*** - **Gamete intrafallopian transfer (GIFT)** involves the transfer of both sperm and eggs directly into the fallopian tube, where **fertilization occurs naturally** within the body. - The step of **fertilization in the lab** (in vitro fertilization) is characteristic of **IVF**, not GIFT. *Transfer of unfertilized egg into the fallopian tube* - In GIFT, **harvested eggs** (oocytes) are mixed with sperm and then immediately **transferred into the fallopian tube**. - This allows natural fertilization to occur within the woman's body, which is a key distinction of GIFT from IVF. *Ovulation stimulation* - Before GIFT, women undergo **controlled ovarian hyperstimulation** to produce multiple mature follicles and increase the chances of successful egg retrieval. - This process is essential for obtaining a sufficient number of **oocytes** for transfer. *Oocyte retrieval* - Once the follicles are mature, **oocytes are retrieved** from the ovaries, typically through transvaginal ultrasound-guided aspiration. - These retrieved oocytes are then prepared for transfer along with sperm into the fallopian tubes.
Question 6: Continuous GnRH therapy is used in All EXCEPT.
- A. Precocious puberty
- B. Prostate cancer
- C. Male infertility (Correct Answer)
- D. Endometriosis
Explanation: ***Male infertility*** - **Pulsatile GnRH therapy** is used to stimulate gonadotropin secretion and subsequent testosterone production in hypogonadotropic hypogonadism, which can cause male infertility. - **Continuous GnRH therapy** causes downregulation of GnRH receptors leading to suppression of gonadotropin release, which would worsen male infertility. *Precocious puberty* - Continuous GnRH therapy (GnRH agonists) is used to suppress the **pituitary-gonadal axis**, effectively stopping the progression of precocious puberty. - By continuously stimulating GnRH receptors, it leads to their **desensitization and downregulation**, preventing the pulsatile release of LH and FSH. *Prostate cancer* - Continuous GnRH therapy (GnRH agonists) is used for **androgen deprivation therapy**, suppressing testosterone production, which fuels prostate cancer growth. - This effectively creates a chemical castration effect by **downregulating GnRH receptors** on pituitary gonadotrophs. *Endometriosis* - Continuous GnRH therapy (GnRH agonists) is used to induce a **hypoestrogenic state**, which helps shrink endometrial implants. - By continuously stimulating GnRH receptors, it leads to their **desensitization and downregulation**, reducing estrogen production from the ovaries.
Question 7: What is the most distinctive functional characteristic of the barrier method shown?
- A. Can be retained in vagina for extended periods (Correct Answer)
- B. More effective than male condom
- C. Must be inserted immediately after coitus
- D. Consists of nonoxynol-9 impregnated latex
Explanation: ***Can be retained in vagina for extended periods*** - The image displays a **contraceptive sponge**, which can be inserted up to 24 hours before intercourse and provides continuous protection for that duration, allowing for multiple acts of coitus. - It must be left in place for at least **6 hours after the last intercourse** but not for more than **30 hours in total**. - This extended retention capability is a **distinctive feature** of the contraceptive sponge compared to other barrier methods. *More effective than male condom* - The **contraceptive sponge** has a **higher failure rate** (typical use: 12-24% for parous women, 9-12% for nulliparous women) compared to male condoms (typical use failure rate of 13%). - Male condoms are generally **more effective** in preventing pregnancy and provide additional protection against sexually transmitted infections (STIs). *Must be inserted immediately after coitus* - The contraceptive sponge is designed for **pre-coital insertion**, not post-coital use. - It should be inserted **before intercourse** to be effective, as its mechanism relies on trapping sperm and releasing spermicide continuously. - It remains effective for multiple acts of intercourse within the 24-hour insertion window. *Consists of nonoxynol-9 impregnated polyurethane* - While this statement is **technically accurate** (the contraceptive sponge is made of polyurethane foam impregnated with 1000mg of nonoxynol-9), it describes the **composition** rather than a functional characteristic. - The most **clinically distinctive** feature of the sponge is its extended retention time, making Option A the **best answer** among the choices provided. - This distinguishes the sponge from other barrier methods like diaphragms or cervical caps, which also use spermicide but have different insertion timing requirements.
Question 8: A multidisciplinary team is developing protocols for adolescent gender-affirming care. When evaluating the appropriateness of GnRH analog therapy versus immediate cross-sex hormones in a 16-year-old with persistent gender dysphoria (Tanner stage 5), which factor most strongly supports proceeding directly to cross-sex hormones?
- A. Parental consent is available
- B. Mental health evaluation shows no contraindications
- C. Completion of pubertal development makes GnRH analogs ineffective (Correct Answer)
- D. Patient expresses strong desire for rapid physical changes
Explanation: ***Completion of pubertal development makes GnRH analogs ineffective*** - **GnRH analogs** are primarily used to suppress the progression of endogenous puberty; once a patient has reached **Tanner stage 5**, biological puberty is complete, rendering suppression redundant. - At this physiological stage, initiating **cross-sex hormones** (gender-affirming hormone therapy) is the appropriate clinical step to align physical characteristics with gender identity. *Parental consent is available* - While **parental consent** is a legal and ethical requirement for treating minors, it does not dictate the physiological choice between suppression and hormone therapy. - Consent is necessary for either **GnRH analogs** or **cross-sex hormones**, but the patient's **Tanner stage** is the medical deciding factor here. *Mental health evaluation shows no contraindications* - A thorough **mental health evaluation** is a prerequisite for all gender-affirming medical interventions to ensure the diagnosis of **gender dysphoria**. - While it confirms readiness for treatment, it does not differentiate which specific endocrine intervention is biologically appropriate for a **Tanner 5** adolescent. *Patient expresses strong desire for rapid physical changes* - **Patient autonomy** and goals are vital, but clinical protocols prioritize developmental staging over the desired speed of changes to ensure safety. - Although **cross-sex hormones** do produce rapid changes compared to analogs, the medical rationale for skipping analogs is the **completion of puberty**, not patient preference.
Question 9: A 35-year-old transgender woman desires fertility preservation before starting feminizing hormone therapy. She has limited financial resources. Which option provides the best balance of efficacy, cost, and time efficiency?
- A. Testicular tissue cryopreservation
- B. Sperm banking before hormone initiation (Correct Answer)
- C. Delaying hormone therapy until natural conception
- D. Sperm extraction after 6 months of hormone therapy
Explanation: ***Sperm banking before hormone initiation*** - **Sperm banking** is the gold standard for fertility preservation as it is the most **cost-effective**, non-invasive, and proven method for transgender women. - It should be performed **before** starting feminizing therapy because hormones like **estrogen** and **anti-androgens** suppress the HPG axis and severely impair **spermatogenesis**. *Testicular tissue cryopreservation* - This is currently considered an **experimental technique** and is not standard clinical practice for adult fertility preservation. - It is significantly more **expensive** and requires an invasive surgical procedure (testicular biopsy) compared to simple masturbation for sperm banking. *Delaying hormone therapy until natural conception* - This is often not a viable or desirable option for many patients due to the high risk of worsening **gender dysphoria** during the delay period. - It assumes the patient currently has a partner with whom they can conceive naturally and does not address **long-term fertility** needs. *Sperm extraction after 6 months of hormone therapy* - After 6 months of hormone therapy, **testicular atrophy** and **azoospermia** are common, making extraction via **TESE** much less likely to be successful. - To attempt this, the patient would likely need to **discontinue hormone therapy** for months, leading to a return of secondary masculine characteristics and significant psychological distress.
Question 10: A 28-year-old transgender man presents 6 months after initiating testosterone therapy with persistent vaginal bleeding despite amenorrhea for 4 months. Labs show testosterone 650 ng/dL and hemoglobin 9.2 g/dL. What is the most appropriate next step?
- A. Perform transvaginal ultrasound and endometrial sampling (Correct Answer)
- B. Add progestin therapy
- C. Increase testosterone dose
- D. Discontinue testosterone and observe
Explanation: ***Perform transvaginal ultrasound and endometrial sampling*** - Unexpected **vaginal bleeding** after achieving amenorrhea in a transgender man requires investigation to rule out **endometrial hyperplasia** or malignancy. - Although testosterone causes vaginal atrophy, it can also be **aromatized into estrogen**, potentially leading to endometrial proliferation; investigation is warranted given the significant **anemia**. *Add progestin therapy* - While progestins are used to stop heavy bleeding, they should not be started before a **diagnostic evaluation** of the endometrium has been performed in this context. - Adding progestin without a diagnosis could mask **underlying pathology** like malignancy or structural abnormalities. *Increase testosterone dose* - The patient's testosterone level (650 ng/dL) is already within the **physiologic male range** (300-1000 ng/dL). - Increasing the dose may lead to higher rates of **aromatization to estrogen**, potentially worsening the endometrial issues rather than stopping the bleeding. *Discontinue testosterone and observe* - Discontinuing gender-affirming therapy can cause significant **psychological distress** and is not the standard first step for investigating bleeding. - Observation is inappropriate here because the patient is **anemic** and requires an active diagnostic workup to identify the source of blood loss.
Want unlimited practice?
Get full access to all questions, explanations, and performance tracking.
Start For Free